DMF FILING IN US, EUROPE AND CANADA
Journal Title: International Journal of Drug Regulatory Affairs - Year 2015, Vol 3, Issue 4
Abstract
A Drug Master File or DMF is a reference source that provides drug evaluator’s confidential information not available to drug product manufacturer about the specific process and components used in the manufacturing, processing and packaging of a drug meant for Human/Animal use. The submission of a DMF is not required by law or FDA regulation. A DMF is submitted solely at the discretion of the holder. The information contained in the DMF may be used to support an Investigational New Drug Application (IND), a New Drug Application (NDA), an Abbreviated New Drug Application (ANDA), another DMF, or amendments and supplements to any of these.
Authors and Affiliations
Agarwal Pooja, Badjatya J. K
Keywords
Related Articles
- EP ID EP339251
- DOI -
- Views 97
- Downloads 0
FORMULATION AND DEVELOPMENT OF KETOPROFEN BILAYER TABLETS
Aim of present research work was formulation and development of bilayer tablets of Ketoprofen to reduce the side effects of Ketoprofen and to improve the therapeutic benefits and patients’ compliance to treatment. Bi-lay...
PREPARATION & COMPILATION OF ACTD DOSSIER (PART II QUALITY)
ACTD is a critical document for drug substance and produces registration in ASEAN region. The document is essentially divided into 4 parts. Each part provides information under specific head. Out of all the parts, the pa...
THE NEW REGULATIONS FOR THE APPROVAL OF MEDICINAL PRODUCTS IN IVORY COAST: APPLICATION OF REGULATION N ° 06/2010 / CM / WAEMU RELATING TO PROCEDURES FOR THE APPROVAL OF PHARMACEUTICAL PRODUCTS FOR HUMAN USE IN WAEMU MEMBER STATES
Harmonization of procedures for the approval of medicines in the WAEMU area allows Member States to have a standard tool for the examination of applications for marketing authorization for medicinal products for human us...
CONCEPT OF 505 (b) (2) APPLICATION: BENEFITS AND CHALLENGES
A 505(b) (2) application is a new drug application (NDA) delineated in section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.505(b)(2) application is one that one or a lot of the investigations relied upon by the...
IMPORTANCE OF DEFICIENCY RESPONSE IN PHARMACEUTICAL ENVIRONMENT FOR DRUG APPROVAL
This illustrates examples of series deficiencies, that’s how really company faces problem due to deficiency. It’s to convey the message if drug product manufacturer can visualize earlier all aspect of risks and manifest...